Table 2.
Represented clinical trials
| Drug name | Material | Conditions | Delivery route | Trial register | Status | Phase | Last update posted |
|---|---|---|---|---|---|---|---|
| EGFR(V)-EDV-Dox | bacterially derived minicell | glioblastoma, astrocytoma | intravenous | NCT02766699 | recruiting | phase 1 | 2019 |
| AVXS-101 | AAV9 | spinal muscular atrophy | intravenous | NCT04851873 | completed | phase 3 | 2023 |
| Skysona | lentiviral | cerebral adrenoleukodystrophy | intravenous | NCT03852498 | active, not recruiting | phase 3 | 2022 |
| DNX-2401 | adenovirus | recurrent high-grade glioma | intraarterial | NCT03896568 | recruiting | phase 1 | 2023 |
| MSCs-Exos | exosome | Alzheimer’s disease | intranasal | NCT04388982 | unknown | phase 1, phase 2 | 2021 |
| LipoCurc | liposome | glioblastoma | intravenous | NCT05768919 | recruiting | phase 1, phase 2 | 2023 |
| AGuIX | polymeric NPs | brain metastases | intravenous | NCT03818386 | recruiting | phase 2 | 2022 |
| NU-0129 | AuNP | gliosarcoma | intravenous | NCT03020017 | completed | early phase 1 | 2022 |
| ExAblate, Definity | microbubbles | Alzheimer’s disease | intravenous | NCT02986932 | completed | not applicable | 2018 |
| Implantable ultrasound device SonoCloud-9 + Abraxane | microbubbles | glioblastoma | intravenous | NCT04528680 | recruiting | phase 1, phase 2 | 2022 |
| MTX110 | NPs | glioma | convection-enhanced delivery | NCT04264143 | recruiting | phase 1 | 2022 |
| Nanoliposomal irinotecan | lipid-based NPs | high-grade glioma | convection-enhanced delivery | NCT02022644 | active, not recruiting | phase 1 | 2022 |
| APH-1105 | NPs | Alzheimer’s disease | intranasal | NCT03806478 | not yet recruiting | phase 2 | 2021 |
| Cytarabine | liposome | central nervous system metastases | intrathecal | NCT00992602 | completed | phase 2 | 2017 |
| GLIADEL | wafer | metastatic brain cancer | intraparenchymal | NCT00525590 | completed | phase 2 | 2020 |
| CD19-CAR T cells | lymphocyte | central nervous system lymphoma | intracerebroventricular | NCT05625594 | recruiting | phase 1 | 2022 |